Comparison reveals serum homocysteine as a biomarker for COPD severity in patients with acute exacerbations, suggesting deeper insights into systemic inflammation.
Objectives: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Acute exacerbations of COPD significantly impact disease progression and patient outcomes. Serum homocysteine, a potential biomarker of systemic inflammation and oxidative stress, may play a role in COPD pathophysiology. This study aims to compare serum homocysteine levels between stable COPD patients and those experiencing acute exacerbations. Material and Methods: Serum homocysteine levels were analyzed by enzymatic assay from the stable and acute exacerbation groups and correlated with the severity of COPD, along with erythrocyte sedimentation rate ( ESR ) and COPD assessment test (CAT) score results. Results: The serum homocysteine levels were significantly higher in the acute exacerbation group (18.2 + 7.6) compared to the stable COPD group (15.8 + 5.2). Higher serum homocysteine levels were seen in patients with higher CAT and ESR scores. Conclusion: Serum homocysteine is a valuable indicator associated with acute exacerbation of COPD. It also serves as a marker of disease severity in conjunction with ESR and CAT scores.
No takes yet. Share an insight, caveat, or question.
Adarsh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: